Specialty Pharmacy

New trials reveal xanomeline and trospium effectively alleviate schizophrenia symptoms, offering a novel treatment option with minimal adverse effects.

In chronic hepatitis B (CHB) mouse models, the ferritin nanoparticle-preS1 (ferritin-NP-preS1) with small interfering RNA (siRNA) showed 100% and sustained serum HBsAg over an approximate 11-month period.

New trial results highlight intravenous immunoglobulin (IVIG) 10% as an effective rescue treatment for relapsing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), enhancing patient care and pharmacist involvement in management.

Paula E. Voinescu, PhD, MD, emphasized the need for additional research in this area, noting it is both “surprising and upsetting.”

The condition, which is common in patients with chronic kidney disease (CKD), is characterized by skin lesions and currently has no curative treatment.

In the treatment of metabolic dysfunction-associated steatohepatitis (MASH), engineered extracellular vesicles helped mitigate disease progression and did not compromise bone density.

Specialty pharmacies must develop comprehensive health equity programs that address diverse patient needs.

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective VEGF inhibition.

The Inflation Reduction Act of 2022 (IRA) drug negotiation provisions will fundamentally reshape Medicare drug pricing, provider reimbursement, and health care delivery dynamics across Part B and commercial markets, according to panelists at Asembia’s AXS25 Summit.

Specialty pharmacies can leverage advanced analytics, AI, and comprehensive data insights to create targeted clinical programs.

Specialty distributors provide strategic partnerships that enhance pharmaceutical manufacturers' ability to bring innovative medicines to market.

Nipocalimab the first and only FcRn blocker approved in anti-acetylcholine receptor– or anti-muscle-specific kinase adults and children with generalized myasthenia gravis.

As the cell and gene therapy pipeline expands, experts at Asembia’s AXS25 Summit emphasized the need for error-proof logistics, value-based access strategies, and coordinated reimbursement models.

At Asembia’s AXS25 Summit, Shea Hudson spotlighted how pharmacists are transforming into essential clinical partners through advanced technology, patient advocacy, and value-based collaboration.

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

FDA approves Zevaskyn, the first gene therapy for RDEB, offering hope for effective wound healing and pain relief in patients.

Experts at Asembia’s AXS25 Summit discussed the economics of specialty pharmacy for rare diseases, addressing high treatment costs and strategies for balancing innovation.

Integrating community pharmacists into specialty pharmacy care can enhance patient access, address physician shortages, and expand pharmacists' roles in delivering high-quality clinical services, according to experts at Asembia’s AXS25 Summit.

The Asembia AXS25 Summit will include the latest news and expert insights in the specialty pharmacy field.

NS-229 is a Janus kinase 1 (JAK1) inhibitor being investigated in eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition that can cause severe allergic and asthmatic symptoms through inflammation of nerve cells.

The treatment received indications as a monotherapy and in combination regimen with carboplatin or cisplatin and gemcitabine.

A study reveals IVIG treatment shows no significant benefits over tocilizumab for severe COVID-19, highlighting higher adverse events and costs.

The investigators’ hypothesis is supported by phase 2 trial data in which hydronidone resulted in significant reversal of liver fibrosis in patients with chronic hepatitis B (CHB).

This component of scar tissue may have a role in kidney fibrosis for slowing disease progression and improving outcomes for patients with chronic kidney disease (CKD).

The in vivo gene editing program is designed to eliminate cccDNA and inactive integrated hepatitis B DNA.

The breakthrough designation is supported by clinical data from ongoing phase 1/2 trials.

Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.